![Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India](https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg?p=facebook)
Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India
![Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) | Cardiovascular Diabetology | Full Text Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1475-2840-11-92/MediaObjects/12933_2012_Article_520_Fig1_HTML.jpg)
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) | Cardiovascular Diabetology | Full Text
![Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD | American Society of Nephrology Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD | American Society of Nephrology](https://cjasn.asnjournals.org/content/clinjasn/15/12/1728/F1.large.jpg)
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD | American Society of Nephrology
![Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial - The Lancet Diabetes & Endocrinology Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial - The Lancet Diabetes & Endocrinology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f8fb85cf-f933-47cc-9fd4-08f73c32ac30/gr1_lrg.jpg)
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial - The Lancet Diabetes & Endocrinology
![These highlights do not include all the information needed to use STEGLUJAN safely and effectively. See full prescribing information for STEGLUJAN. STEGLUJAN® (ertugliflozin and sitagliptin) tablets, for oral use Initial U.S. Approval: These highlights do not include all the information needed to use STEGLUJAN safely and effectively. See full prescribing information for STEGLUJAN. STEGLUJAN® (ertugliflozin and sitagliptin) tablets, for oral use Initial U.S. Approval:](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=steglujan-06.jpg&id=646085)
These highlights do not include all the information needed to use STEGLUJAN safely and effectively. See full prescribing information for STEGLUJAN. STEGLUJAN® (ertugliflozin and sitagliptin) tablets, for oral use Initial U.S. Approval:
![NDC 0006-0080 Janumet XR Sitagliptin And Metformin Hydrochloride Tablet, Film Coated, Extended Release Oral NDC 0006-0080 Janumet XR Sitagliptin And Metformin Hydrochloride Tablet, Film Coated, Extended Release Oral](https://ndclist.com/assets/spl/images/64beb3d2-3aeb-4cd5-ba11-dacf6c9a5b50/janumetxr-06.jpg)